LV12083A - N-propargil-1-aminoindana R- enantiomera ta salu un kompoziciju izmantosana - Google Patents
N-propargil-1-aminoindana R- enantiomera ta salu un kompoziciju izmantosanaInfo
- Publication number
- LV12083A LV12083A LV970267A LV970267A LV12083A LV 12083 A LV12083 A LV 12083A LV 970267 A LV970267 A LV 970267A LV 970267 A LV970267 A LV 970267A LV 12083 A LV12083 A LV 12083A
- Authority
- LV
- Latvia
- Prior art keywords
- aminoindan
- propargyl
- islands
- enantiomer
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/446,439 US5744500A (en) | 1990-01-03 | 1995-05-22 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
PCT/US1996/007465 WO1996037199A1 (en) | 1995-05-22 | 1996-05-22 | Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
LV12083A true LV12083A (lv) | 1998-07-20 |
LV12083B LV12083B (lv) | 1998-09-20 |
Family
ID=23772591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-97-267A LV12083B (lv) | 1995-05-22 | 1998-01-20 | N-propargil-1-aminoindana r-enantiomēra, tā sāļu un kompozīciju izmantošana |
Country Status (22)
Country | Link |
---|---|
US (6) | US5744500A (lv) |
EP (1) | EP0828485A4 (lv) |
JP (1) | JP3341898B2 (lv) |
KR (1) | KR100412154B1 (lv) |
CN (1) | CN1096853C (lv) |
AU (1) | AU699090B2 (lv) |
BR (1) | BR9608733A (lv) |
CA (1) | CA2221458A1 (lv) |
CZ (1) | CZ288724B6 (lv) |
EE (1) | EE03741B1 (lv) |
HK (1) | HK1015269A1 (lv) |
HU (1) | HUP9901629A3 (lv) |
IL (1) | IL118247A (lv) |
LT (1) | LT4455B (lv) |
LV (1) | LV12083B (lv) |
MX (1) | MX9708977A (lv) |
NO (1) | NO975331L (lv) |
NZ (1) | NZ308866A (lv) |
PL (1) | PL184124B1 (lv) |
RU (1) | RU2203653C2 (lv) |
SK (1) | SK283675B6 (lv) |
WO (1) | WO1996037199A1 (lv) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5726969A (en) * | 1994-12-28 | 1998-03-10 | Matsushita Electric Industrial Co., Ltd. | Optical recording medium having dual information surfaces |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
CA2387394C (en) | 1999-10-27 | 2009-08-18 | Teva Pharmaceutical Industries, Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
DK1441708T3 (da) | 2001-11-05 | 2009-07-06 | Krele Pharmaceuticals Llc | Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
WO2004041151A2 (en) * | 2002-11-07 | 2004-05-21 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
EP2526944B1 (en) | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20040176430A1 (en) * | 2002-11-21 | 2004-09-09 | Jeffrey Sterling | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
CN1605336A (zh) | 2003-10-10 | 2005-04-13 | 中国医学科学院药物研究所 | 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用 |
US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
CA2547053C (en) | 2003-11-25 | 2014-05-27 | Technion Research & Development Foundation Ltd. | Compositions and methods for treatment of cardiovascular disorders and diseases |
JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
US20050197365A1 (en) * | 2004-02-27 | 2005-09-08 | Jeffrey Sterling | Diamino thiazoloindan derivatives and their use |
CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
WO2006014968A2 (en) * | 2004-07-27 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
DK2332408T3 (da) | 2005-02-17 | 2013-12-02 | Biogen Idec Inc | Behandling af neurologiske sygdomme |
WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
RU2404746C2 (ru) | 2005-02-23 | 2010-11-27 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина с улучшенной однородностью содержимого |
US8022104B2 (en) * | 2005-02-24 | 2011-09-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Formulations of ladostigil tartrate |
WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
EP1888056A4 (en) * | 2005-06-01 | 2008-09-03 | Teva Pharma | USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS |
FR2886549B1 (fr) * | 2005-06-06 | 2007-09-07 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux |
US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
US7491847B2 (en) * | 2005-11-17 | 2009-02-17 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
JP2009518433A (ja) * | 2005-12-09 | 2009-05-07 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム | 神経保護用の低用量ラドスチギルの使用 |
US20110047685A1 (en) * | 2006-02-16 | 2011-03-03 | Ferrara Vincent R | Impact energy management method and system |
US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
AU2007235517B2 (en) * | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
CN101062897B (zh) * | 2006-04-25 | 2011-11-23 | 重庆医药工业研究院有限责任公司 | 一种制备2,3-二氢-1h-茚-1-胺及其衍生物的改进方法 |
EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
CA2672414A1 (en) * | 2006-12-14 | 2008-06-26 | Teva Pharmaceutical Industries Ltd. | Crystalline solid rasagiline base |
BRPI0718339A2 (pt) * | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
CA2698695A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
CN101909438A (zh) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | 雷沙吉兰制剂、其制备及用途 |
US20110105788A1 (en) * | 2008-03-28 | 2011-05-05 | Medichem, S.A. | Polymorphic Form of an Aminoindan Mesylate Derivative |
PL2285769T3 (pl) * | 2008-06-02 | 2015-01-30 | Generics Uk Ltd | Sposób otrzymywania enancjomerycznie czystych amin |
US20110184071A1 (en) * | 2008-06-02 | 2011-07-28 | Vinayak Gore | process for the preparation of amines |
ES2389353T3 (es) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
NZ589445A (en) * | 2008-06-13 | 2013-06-28 | Teva Pharma | Rasagiline for parkinson's disease modification |
US8334409B2 (en) * | 2008-06-19 | 2012-12-18 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
WO2009154777A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing and drying solid rasagiline base |
EA201170181A1 (ru) | 2008-07-11 | 2011-08-30 | Синтон Бв | Полиморфные формы разагилина гидрохлорида |
WO2010013048A1 (en) * | 2008-07-30 | 2010-02-04 | Generics [Uk] Limited | Polymorphic form of rasagiline mesylate |
EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
EP2417101B1 (en) * | 2009-04-09 | 2013-10-23 | Merck Sharp & Dohme B.V. | Indane derivatives |
JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
CN102048717B (zh) † | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
US8741962B2 (en) * | 2009-11-26 | 2014-06-03 | Usv Limited | Process for preparation of Rasagiline and salts thereof |
EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
JP6045347B2 (ja) | 2010-02-03 | 2016-12-14 | ファーマ ツー ビー リミテッド | ラサギリンの持続放出性製剤およびその使用 |
EP2563347B1 (en) | 2010-04-30 | 2016-10-12 | Teikoku Pharma USA, Inc. | Propynylaminoindan transdermal compositions |
JP2013533287A (ja) | 2010-07-27 | 2013-08-22 | テバ ファーマシューティカル インダストリーズ リミティド | 嗅覚機能不全の処置のためのラサギリンの使用 |
WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
CA2809966C (en) | 2010-09-01 | 2019-01-08 | Tonix Pharmaceuticals, Inc. | Treatment for cocaine addiction |
KR20140023872A (ko) | 2010-10-26 | 2014-02-27 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소 농축 라사길린 |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
CN103476404B (zh) | 2011-03-24 | 2017-09-29 | 帝国制药美国公司 | 包含活性剂层和活性剂转化层的透皮组合物 |
JP2014534197A (ja) | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−メチル−プロパルギルアミノインダン |
MX2014004308A (es) | 2011-10-10 | 2014-07-24 | Teva Pharma | R(+)-n-formil-propargil-aminoindan. |
WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
EP2827848B1 (en) | 2012-03-21 | 2016-04-27 | Synthon BV | Stabilized pharmaceutical compositions comprising rasagiline salts |
WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
AR092168A1 (es) | 2012-08-17 | 2015-03-25 | Teva Pharma | Formulaciones parenterales de rasagilina |
SG11201502681WA (en) | 2012-11-02 | 2015-05-28 | Teikoku Pharma Usa Inc | Propynylaminoindan transdermal compositions |
ES2524865T1 (es) * | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata |
ES2502140T1 (es) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
WO2014141280A1 (en) * | 2013-03-13 | 2014-09-18 | Abital Pharma Pipelines Ltd. | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
CN103804200B (zh) * | 2014-02-21 | 2015-04-29 | 常州市第四制药厂有限公司 | 雷沙吉兰及其类似物的制备方法 |
US11701340B2 (en) * | 2019-04-17 | 2023-07-18 | Vici Health Sciences., Llc | Liquid pharmaceutical compositions |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
US513244A (en) * | 1894-01-23 | Island | ||
US3253037A (en) * | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
GB1037014A (en) | 1963-08-02 | 1966-07-20 | Aspro Nicholas Ltd | Derivatives of 1-aminoindane |
US3513249A (en) * | 1968-12-24 | 1970-05-19 | Ideal Ind | Explosion connector with improved insulating means |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
DE3779500T2 (de) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
EP0258096B1 (fr) | 1986-08-21 | 1992-09-09 | Roussel-Uclaf | Dérivés de l'indane, leur procédé de préparation, leur application à titre de médicaments, les compositions pharmaceutiques les renfermant et les intermédiaires obtenus |
HU197510B (en) | 1986-12-19 | 1989-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
CA1327795C (en) | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
FR2626877B1 (fr) | 1988-02-05 | 1991-04-05 | Delalande Sa | Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique |
HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
JPH04504760A (ja) | 1989-09-25 | 1992-08-20 | アメリカ合衆国 | 炎症性反応の検出およびストレスに対する応答の予測をするための評価方法 |
JP3412694B2 (ja) | 1989-10-02 | 2003-06-03 | シーマ・ラブス、インコーポレイテッド | 発泡性投与剤 |
FR2655044B1 (fr) | 1989-11-24 | 1995-03-03 | Delalande Sa | Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique. |
JPH03176457A (ja) | 1989-12-04 | 1991-07-31 | Nippon Paint Co Ltd | 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材 |
IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
CA2039742A1 (en) | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
US5767164A (en) * | 1991-04-04 | 1998-06-16 | Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5444095A (en) * | 1991-04-04 | 1995-08-22 | University Of Toronto, Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
IL112819A (en) | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
NZ246091A (en) * | 1991-12-24 | 1995-08-28 | Yamanouchi Pharma Co Ltd | Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
AU4534593A (en) | 1992-06-12 | 1994-01-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
SE501848C2 (sv) | 1992-11-18 | 1995-06-06 | Kvaerner Pulping Tech | Metod att koka massa kontinuerligt vid konstant temperatur |
IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
IL112779A (en) | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
EE04039B1 (et) | 1995-03-02 | 2003-06-16 | R.P. Scherer Limited | Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine |
IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
WO1999037293A2 (en) * | 1998-01-27 | 1999-07-29 | Thomas Thomas N | Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders |
FI104042B (fi) * | 1998-09-29 | 1999-11-15 | Aaro Kiuru | Menetelmä keuhkojen perfuusion mittaamiseksi |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
PL370793A1 (en) * | 2001-07-04 | 2005-05-30 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US20060009483A1 (en) * | 2002-05-31 | 2006-01-12 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
WO2004026453A2 (en) * | 2002-09-06 | 2004-04-01 | Genteric, Inc. | Microcapsules and methods of use |
EP2526944B1 (en) * | 2002-11-15 | 2016-06-01 | Teva Pharmaceutical Industries Limited | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
RU2404746C2 (ru) * | 2005-02-23 | 2010-11-27 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина с улучшенной однородностью содержимого |
-
1995
- 1995-05-22 US US08/446,439 patent/US5744500A/en not_active Expired - Lifetime
-
1996
- 1996-05-14 IL IL11824796A patent/IL118247A/en not_active IP Right Cessation
- 1996-05-22 PL PL96323470A patent/PL184124B1/pl not_active IP Right Cessation
- 1996-05-22 EE EE9700310A patent/EE03741B1/xx not_active IP Right Cessation
- 1996-05-22 CN CN96195710A patent/CN1096853C/zh not_active Expired - Fee Related
- 1996-05-22 NZ NZ308866A patent/NZ308866A/en not_active IP Right Cessation
- 1996-05-22 AU AU58723/96A patent/AU699090B2/en not_active Expired
- 1996-05-22 BR BR9608733-1A patent/BR9608733A/pt not_active Application Discontinuation
- 1996-05-22 US US08/952,705 patent/US6316504B1/en not_active Expired - Lifetime
- 1996-05-22 MX MX9708977A patent/MX9708977A/es unknown
- 1996-05-22 KR KR1019970708371A patent/KR100412154B1/ko not_active IP Right Cessation
- 1996-05-22 JP JP53584496A patent/JP3341898B2/ja not_active Expired - Fee Related
- 1996-05-22 CZ CZ19973699A patent/CZ288724B6/cs not_active IP Right Cessation
- 1996-05-22 WO PCT/US1996/007465 patent/WO1996037199A1/en not_active Application Discontinuation
- 1996-05-22 SK SK1574-97A patent/SK283675B6/sk unknown
- 1996-05-22 EP EP96920401A patent/EP0828485A4/en not_active Ceased
- 1996-05-22 CA CA002221458A patent/CA2221458A1/en not_active Abandoned
- 1996-05-22 HU HU9901629A patent/HUP9901629A3/hu unknown
- 1996-05-22 RU RU97121002/14A patent/RU2203653C2/ru not_active IP Right Cessation
-
1997
- 1997-11-20 NO NO975331A patent/NO975331L/no not_active Application Discontinuation
- 1997-12-22 LT LT97-200A patent/LT4455B/lt not_active IP Right Cessation
-
1998
- 1998-01-20 LV LVP-97-267A patent/LV12083B/lv unknown
-
1999
- 1999-01-27 HK HK99100353A patent/HK1015269A1/xx not_active IP Right Cessation
-
2001
- 2001-10-26 US US10/016,268 patent/US6630514B2/en not_active Expired - Fee Related
-
2002
- 2002-11-27 US US10/305,478 patent/US6956060B2/en not_active Expired - Fee Related
-
2005
- 2005-06-17 US US11/155,864 patent/US20060094783A1/en not_active Abandoned
-
2006
- 2006-11-10 US US11/595,726 patent/US20070100001A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV12083A (lv) | N-propargil-1-aminoindana R- enantiomera ta salu un kompoziciju izmantosana | |
FI945657A (fi) | Proteesi | |
DE69618587D1 (de) | Chinazoline und pharmazeutische zusammensetzungen | |
DK1093815T3 (da) | Oral 2-methyl-thieno-benzodiazepinformulering | |
DE69420988D1 (de) | Zahnärztliche Ausgabeeinrichtung | |
UY24316A1 (es) | Composiciones refrescantes | |
DK0804078T3 (da) | Sammensætning og anvendelse deraf | |
BR9607058A (pt) | Composição | |
BR9606809A (pt) | Composição inseticidamente ativa | |
DE69620642D1 (de) | Reiningungsverfahren und-zusammensetzung | |
NO973471D0 (no) | Transdermal formulering | |
PT728814E (pt) | Composicao betuminosa | |
BR9607722A (pt) | Formulação transdérmica | |
DE69428788D1 (de) | Parfumzusammensetzung | |
BR9609903A (pt) | ComposiçÃo inseticidamente ativa | |
DE69616374T2 (de) | Germizide zusammensetzung | |
ITMI931125A1 (it) | Composizioni dentarie adesive e di ricostruzione | |
DE69430362D1 (de) | Ektoparasitizide formulierung | |
FI973280A (fi) | Farmaseuttinen koostumus | |
BR9607946A (pt) | Composição | |
BR9605777A (pt) | Composição farmacêutica | |
BR9605220A (pt) | Gonadotropinas e composiçao farmacêutica | |
BR9605131A (pt) | Composição farmacêutica | |
LV10012A (lv) | Smarzvielu kompozicija | |
LV10722A (lv) | Smarzvielu kompozicija |